Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Finished

eVai A novel bioinformatics SaaS platform to identify and classify the pathogenicity of single genomic variants and oligogenic variant combinations for the diagnosis and treatment of genetic diseases

Coordinator
Engenome SRL, Italy
Runs
1 April 2022 to 31 March 2024
Status
Finished
EU funding
€1.7m
Total cost
€2.4m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190164416

What the project is doing

In the project's own words, from its summary on CORDIS.

Genetic diseases affect +300 million individuals worldwide, resulting in 2.8 million new patients every year. The advent of Next Generation Sequencing (NGS) means its now possible to analyze the whole patients genome. However, variant interpretation is the biggest hindrance to widespread adoption of NGS technologies. Hence, clinicians are struggling to identify disease-causing variants and the diagnostic yield of genetic disorders is only about 50% on average. eVai is a revolutionary SaaS platform that allows geneticists to identify multiple pathogenic genomic variants with unprecedented accuracy and speed.

We bring to market [1] first and only digenic and oligogenic variant interpretation [2] best predictive causative variants accuracy; [3] reduced turnaround time; and [4] consistency of variant interpretation; [5] discovery of unknown variants.

Topics

Who is involved

OrganisationCityCountryRole
Engenome SRLPaviaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI